Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene

Infection and Immunity

Volumn 65, Issue 5, 1997, Pages 1584-1592

  Chang, Yun C ^a   Cherniak, Robert ^b   Kozel, Thomas R ^c   Granger, Donald L ^d   Morris, Laura C ^b   Weinhold, Leanne C ^c   Kwon Chung, K J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEVADA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE;

ANIMAL CELL; ARTICLE; BACTERIAL MEMBRANE; CRYPTOCOCCUS NEOFORMANS; FEMALE; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STRAIN DIFFERENCE; VIRULENCE;

EID: 0030899780     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.5.1584-1592.1997     Document Type: Article

References (35)

1. Belay, T., and R. Cherniak. 1995. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosor-bent assay. Infect. Immun. 63:1810-1819.
2. Bulmer, G. S., and M. D. Sans. 1967. Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J. Bacteriol. 94:1480-1483.
3. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912-4919.
4. Chang, Y. C., L. A. Penoyer, and K. J. Kwon-Chung. 1996. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect. Immun. 64:1977-1983.
5. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect. Immun. 59:59-64.
6. Cherniak, R., L. C. Morris, T. Belay, E. D. Spitzer, and A. Casadevall. 1995. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun. 63:1899-1905.
7. Collins, H. L., and G. J. Bancroft. 1991. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect. Immun. 59: 3883-3888.
8. Dong, Z. M., and J. W. Murphy. 1995. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect. Immun. 63:770-778.
9. Edman, J. C., and K.J. Kwon-Chung. 1990. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol. Cell. Biol. 10:4538-4544.
10. Fine, D. P., S. R. Marney, Jr., D. G. Colley, J. S. Sergent, and R. M. Des Prez. 1972. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109:807-809.
11. Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126:131-138.
12. Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, and C. A. Nacy. 1990. Leishmania major amastigotes initiate the L -arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J. Immunol. 145:4290-4297.
13. Hibbs, J. B., Jr., R. R. Taintor, and Z. Vavrin. 1987. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235:473-476.
14. Keller, R. G., G. S. Pfrommer, and T. R. Kozel. 1994. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect. Immun. 62:215-220.
15. Kozel, T. R. 1995. Virulence factors of Cryptococcus neoformans. Trends Microbiol. 3:295-299.
16. Kozel, T. R., and J. J.Cazin. 1971. Non-encapsulated variant of Cryptococcus neoformans. I. Virulence studies and characterization of soluble polysaccharide. Infect. Immun. 3:287-294.
17. Kozel, T. R., M. A. Wilson, and J.W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59:3101-3110.
18. Kozel, T. R., M. A. Wilson, and W. H. Welch. 1992. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:3122-3127.
19. Kwon-Chung, K. J. 1975. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Myeologia 67:1197-2000.
20. Kwon-Chung, K. J., J. C. Edman, and B. L. Wickes. 1992. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect. Immun. 60:602-605.
21. Kwon-Chung, K. J., A. Varma, J. C. Edman, and J. E. Bennett. 1992. Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J. Med. Vet. Mycol. 30:61-69.
22. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145:4306-4310.
23. Lorsbach, R. B., and S. W. Russell. 1992. A specific sequence of stimulation is required to induce synthesis of the antimicrobial molecule nitric oxide by mouse macrophages. Infect. Immun. 60:2133-2135.
24. Macher, A. M., J. E. Bennett, J. E. Gadek, and M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120:1686-1690.
25. McGaw, T, G., and T. R. Kozel. 1979. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect. Immun. 25:262-267.
26. McGee, Z. A., and C. M. Clemens. 1994. Effect of bacterial products on tumor necrosis factor production: quantitation in biological fluids or tissues. Methods Enzymol. 236:23-31.
27. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
28. Murphy, J. A. 1989. Immunoregulation in cryptococcosis. Marcel Dekker, New York. N.Y.
29. Naslund, P. K., W. C. Miller, and D. L. Granger. 1995. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63:1298-1304.
30. Platts-Mills, T. A., and K. Ishizaka. 1974. Activation of the alternate pathway of human complement by rabbit cells. J. Immunol. 113:348-358.
31. Stuehr, D. J., and M. A. Marletta. 1987. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res. 47:5590-5594.
32. Varma, A., and K. J. Kwon-Chung. 1992. DNA probe for strain typing of Cryptococcus neoformans. J. Clin. Microbiol. 30:2960-2967.
33. Vecchiarelli, A., D. Pietrella, M. Dottorini, C. Monari, C. Retini, T. Todisco, and F. Bistoni. 1994. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98:217-223.
34. Wilson, M. A., and T. R. Kozel. 1992. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:754-761.
35. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966-2972.